Orchestra BioMed Holdings, Inc. growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue: +1033.9%
EBITDA: +22.8%
EBIT: +20.1%
EPS: +19.8%
Free cash flow: -1.1%
Operating cash flow: -0.8%

Forward estimates

Revenue: -88.4%
EBITDA: +95.7%
EPS: -0.1%

Three-year CAGR

Revenue: +111.6%
EBITDA: +15.6%
EBIT: +19.4%
Net income: +13.6%
EPS: +16.9%
Free cash flow: +2.7%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.